| Name | COX-2-IN-21 |
|---|
| Description | COX-2-IN-21 (Compound 5c) is a selective and orally active COX-2 inhibitor with an IC50 of 0.039 μM. COX-2-IN-21 shows promising anti-inflammatory potential[1]. |
|---|---|
| Related Catalog | |
| Target |
COX-2:0.039 μM (IC50) COX-1:12.4 μM (IC50) |
| In Vitro | COX-2-IN-21 (Compound 5c) (50 mg/kg) shows better anti-inflammatory activity and is less ulcerogenic than Celecoxib[1]. COX-2-IN-21 (50 mg/kg) displays potent inhibitory effect on the production of PGE2 greater than Celecoxib, decreases rat serum concentrations of both TNF-α (% inhibition = 55.349) and IL-6 (% inhibition = 61.561) in a comparable or better activity to Celecoxib[1]. |
| References |
| Molecular Formula | C21H22N6O4 |
|---|---|
| Molecular Weight | 422.44 |